{"analyses":[{"estimateComment":"A normal score \\< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.","groupDescription":"Overall survival in the Wild-type RAS Efficacy Analysis Set was compared at a significance level of 5% conditional on a significant treatment effect for progression-free survival in the ITT Analysis Set.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0135","paramType":"Normal score","paramValue":"-2.47","statisticalComment":"Log-rank test stratified by randomization factors: geographic region (Europe vs Asia vs rest of world) and ECOG performance status (0 or 1 vs 2).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"11.6","value":"10.0"},{"groupId":"OG001","lowerLimit":"5.2","upperLimit":"7.9","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"128"}],"units":"Participants"}],"description":"A secondary efficacy endpoint was overall survival in participants with wild-type rat sarcoma viral oncogene homolog (RAS) (without mutation in exons 2 \\[codons 12 and 13\\], 3 \\[codons 59 and 61\\], and 4 \\[codons 117 and 146\\] of KRAS and neuroblastoma RAS viral oncogene (NRAS)). In participants with wild-type RAS, RAS mutation status was defined by KRAS exon 2 mutation status per clinical trial assay testing and mutation status of KRAS exon 3 and 4 and NRAS exons 2, 3 and 4 per Sanger bi-directional sequencing. Overall survival was defined as the time from the randomization date to the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date and participants with survival data obtained after the planned analysis data cut-off date had survival censored at the cut-off date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus best supportive care (BSC) until disease progression, withdrawal of consent, death, or intolerance of study drug.","id":"OG000","title":"Panitumumab + BSC"},{"description":"Participants received best supportive care until disease progression, withdrawal of consent, or death.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"Wild-type RAS Efficacy Analysis Set (subset of participants in the ITT Analysis Set without mutation in exon 2, 3, and 4 of KRAS or NRAS)","reportingStatus":"POSTED","timeFrame":"From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).","title":"Overall Survival in Participants With Wild-type RAS","type":"SECONDARY","unitOfMeasure":"months"}